{{expand|time=2013-07-30T09:54:48+00:00}}
{{Medical}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464382941
| IUPAC_name = ''N'',''N''-dimethyl-2-[5-(1''H''-1,2,4-triazol-1-ylmethyl)-1''H''-indol-3-yl]ethanamine
| image = Rizatriptan.svg

<!--Clinical data-->
| tradename = Maxalt
| Drugs.com = {{drugs.com|monograph|maxalt}}
| MedlinePlus = a601109
| pregnancy_category = B1 <small>([[Australia|Au]])</small>, C <small>([[United_States|U.S.]])</small>
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 45%
| protein_bound = 14%
| metabolism = by [[monoamine_oxidase|monoamine oxidase]]
| elimination_half-life = 2–3 hours
| excretion = 82% [[urine|urine]]; 12% [[faeces|faeces]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 145202-66-0
| ATC_prefix = N02
| ATC_suffix = CC04
| ATC_supplemental =  
| PubChem = 5078
| IUPHAR_ligand = 51
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00953
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4900
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = WR978S7QHH
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00675
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 48273
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 905

<!--Chemical data-->
| C=15 | H=19 | N=5 
| molecular_weight = 269.345 g/mol
| smiles = n1cn(nc1)Cc2cc3c(cc2)ncc3CCN(C)C
| InChI = 1/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
| InChIKey = ULFRLSNUDGIQQP-UHFFFAOYAA
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ULFRLSNUDGIQQP-UHFFFAOYSA-N
}}

'''利扎曲坦''' （{{lang-en|Rizatriptan}}，或译为'''利扎曲普坦'''）是一种[[曲坦类药物|曲坦类]][[5-HT1|5-HT1]]激动剂，由[[默克药厂|默克药厂]]为治疗[[偏头痛|偏头痛]]而开发，商品名'''Maxalt'''。

利扎曲坦于1998年6月39号通过[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）审核，它是第二代曲坦类药物。

==用法==
利扎曲坦可以用来治疗头痛，但不能防止头痛再次发作。

==禁用==
* [[冠状动脉性心脏病|冠状动脉性心脏病]]患者


==参考文献==
{{reflist}}


==外部链接==
*[http://www.maxalt.com Maxalt] website by [[Merck_&_Co.|Merck & Co.]] 

<!--spacing-->
{{默克公司}}
{{抗偏头痛药}}
{{色胺}}

[[Category:三唑|Category:三唑]]